Does Blue Cross Blue Shield Cover Praluent (Alirocumab)?

How BCBS Structures Coverage for Praluent

Blue Cross Blue Shield is not a single insurer. It operates as a federation of 34 independent companies covering more than 115 million members across the United States [1]. Each affiliate sets its own formulary, prior authorization criteria, and appeals process. A BCBS plan in Texas may classify Praluent differently than one in Michigan. The Federal Employee Program (FEP), which covers roughly 5.3 million federal workers and dependents, maintains a separate national formulary with its own PCSK9 inhibitor criteria.

Despite this variation, a pattern holds across most affiliates. Praluent appears on the specialty tier of the majority of BCBS formularies. Specialty-tier placement means higher cost-sharing but does not mean denial. It means the plan considers the drug medically appropriate only after clinical criteria have been met and documented.

For patients with established ASCVD, the ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab 75 mg or 150 mg every two weeks reduced major adverse cardiovascular events by 15% compared to placebo over a median 2.8 years of follow-up (HR 0.85 to 95% CI 0.78 to 0.93, P=0.0003) [2]. This trial is the primary evidence base that most BCBS medical policies reference when evaluating coverage requests.

Prior Authorization Criteria Across BCBS Plans

Every BCBS affiliate requires prior authorization for Praluent. The documentation burden varies, but a common set of criteria appears in the majority of plans.

Most affiliates require the prescriber to confirm: a diagnosis of HeFH (confirmed by genetic testing or clinical criteria such as a Simon Broome or Dutch Lipid Clinic Network score) or established ASCVD with LDL cholesterol remaining above goal despite maximally tolerated statin therapy. "Maximally tolerated" typically means the patient has tried at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 8 to 12 weeks, or has documented intolerance to two or more statins [3].

The American College of Cardiology and American Heart Association (ACC/AHA) 2018 cholesterol guidelines recommend PCSK9 inhibitors for patients with clinical ASCVD whose LDL remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy [4]. Several BCBS affiliates have adopted this threshold directly. Others use a higher LDL cutoff of 100 mg/dL or require documentation that ezetimibe was tried and failed before approving a PCSK9 inhibitor.

The FEP formulary generally aligns with the ACC/AHA thresholds but adds its own documentation requirements. FEP prior authorization forms ask for baseline LDL, current LDL on therapy, a list of all lipid-lowering agents tried with dates and doses, and the reason each was discontinued or deemed insufficient.

Approval periods range from 6 to 12 months depending on the affiliate. Reauthorization requires updated lipid panels showing continued LDL response.

Step Therapy Requirements

Step therapy is the rule, not the exception. The majority of BCBS plans require patients to have tried and failed (or been documented as intolerant to) specific medications before Praluent will be approved.

A typical step therapy sequence looks like this. Step one: high-intensity statin for at least 8 weeks. Step two: addition of ezetimibe 10 mg for at least 4 to 8 weeks. Step three: if LDL remains above the plan-defined threshold (usually 70 mg/dL for ASCVD or 100 mg/dL for primary prevention in HeFH), the prescriber may request Praluent.

Some plans skip the ezetimibe step for patients with homozygous familial hypercholesterolemia (HoFH) or those who have had a cardiovascular event within the prior 12 months. A smaller number of affiliates also accept bempedoic acid (Nexletol) as a step therapy alternative before PCSK9 inhibitor approval, though this is not universal.

Statin intolerance alone does not automatically qualify a patient. Most BCBS medical policies define statin intolerance as documented myalgia, myopathy, or rhabdomyolysis on at least two separate statins at the lowest available dose, confirmed by either CK elevation or a validated symptom assessment tool [5].

Formulary Tier Placement and Cost-Sharing

Praluent sits on the specialty tier (Tier 4 or Tier 5) across most BCBS formularies. This distinction matters for out-of-pocket costs.

On a Tier 4 plan, patients typically pay a fixed copay of $100 to $150 per 30-day supply after prior authorization approval. On a Tier 5 (specialty) plan, cost-sharing shifts to coinsurance, often 25% to 33% of the drug's allowed amount. At a list price of approximately $580 per month, 30% coinsurance translates to roughly $174 per month before any manufacturer assistance.

The BCBS FEP Basic Option, for comparison, places PCSK9 inhibitors on its specialty tier with a $60 per prescription copay for a 30-day supply. The FEP Standard Option charges $55 per specialty prescription. These are among the lower cost-sharing amounts in the BCBS federation.

Several BCBS affiliates have negotiated preferred status for one PCSK9 inhibitor over the other (alirocumab vs. evolocumab). If your plan prefers evolocumab (Repatha), your prescriber may need to document why alirocumab is specifically required, or the plan may redirect the prescription to the preferred agent.

Using the Manufacturer Savings Card with BCBS

Sanofi and Regeneron offer a copay assistance program for commercially insured patients prescribed Praluent. Eligible patients may pay as little as $0 per month, with the savings card covering up to a plan-defined maximum per year [6].

The savings card works with most BCBS commercial plans. It does not apply to government-funded insurance, including Medicare, Medicaid, TRICARE, or the BCBS Federal Employee Program. FEP members are classified as federally funded and are ineligible for manufacturer copay cards.

To activate the card, patients can enroll through the Praluent website or by calling the manufacturer's support line. The pharmacy processes the savings card as a secondary payer after BCBS adjudicates the primary claim. If the BCBS plan denies coverage outright (rather than applying a copay), the savings card cannot be used until the denial is overturned.

One important caveat: copay accumulator and copay maximizer programs, which some BCBS affiliates have adopted, may prevent manufacturer copay assistance from counting toward the patient's annual deductible or out-of-pocket maximum. Under these programs, the plan tracks manufacturer payments separately, meaning the patient's true out-of-pocket exposure resets once the savings card's annual cap is reached [7]. Patients should ask their BCBS plan specifically whether a copay accumulator adjustment applies to specialty-tier drugs.

How to Appeal a BCBS Denial for Praluent

A denial is not the final word. BCBS affiliates are required to offer at least one level of internal appeal and, in most states, an external independent review after internal appeals are exhausted.

The process follows a predictable path. First, obtain the denial letter. It must state the specific clinical reason for the denial, such as "LDL threshold not met" or "step therapy not completed." Second, the prescriber submits a written appeal with supporting documentation. Effective appeals include: the patient's complete lipid panel history, a list of all statin and non-statin therapies tried with start and stop dates, documentation of adverse effects, relevant guideline citations (ACC/AHA 2018, NLA 2020), and a letter of medical necessity explaining why alternative therapies are inadequate for this specific patient.

Dr. Seth Baum, president of the American Society for Preventive Cardiology, has noted: "Patients with familial hypercholesterolemia or recurrent ASCVD events on maximally tolerated therapy have a clear evidence-based need for PCSK9 inhibitors. Denial of these medications in appropriately selected patients conflicts with every major cardiovascular guideline published since 2017" [8].

Internal appeals must be decided within 30 days for non-urgent requests or 72 hours for urgent clinical situations. If the internal appeal is denied, patients can request an external review through their state's insurance department. External review decisions are binding on the insurer in most states.

A 2019 analysis published in JAMA Cardiology found that among commercially insured patients who appealed a PCSK9 inhibitor denial, approximately 45% of appeals were ultimately successful [9]. The likelihood of a successful appeal increased when the prescribing physician included peer-reviewed trial data and specific guideline recommendations in the appeal letter.

Clinical Evidence Supporting Coverage

The FDA approved alirocumab in 2015 based on the ODYSSEY clinical trial program, which enrolled more than 23,000 patients across multiple studies [10]. The label indicates alirocumab for adults with HeFH or clinical ASCVD who require additional LDL-C lowering as an adjunct to diet and maximally tolerated statin therapy.

The primary cardiovascular outcomes data come from ODYSSEY OUTCOMES (2018), which randomized 18,924 patients with recent acute coronary syndrome to alirocumab or placebo on top of high-intensity statin therapy. The primary composite endpoint of coronary heart disease death, nonfatal MI, ischemic stroke, or hospitalization for unstable angina occurred in 9.5% of the alirocumab group vs. 11.1% of the placebo group (HR 0.85, P<0.001) [2].

A pre-specified analysis of ODYSSEY OUTCOMES showed the greatest absolute risk reduction in patients with baseline LDL at or above 100 mg/dL, where alirocumab reduced the primary endpoint by 24% compared to placebo [2]. This finding has directly influenced several BCBS affiliates to set their LDL threshold for PCSK9 inhibitor approval at 100 mg/dL rather than the ACC/AHA-recommended 70 mg/dL.

The 2018 ACC/AHA multisociety guideline on the management of blood cholesterol provides a Class IIa recommendation for adding a PCSK9 inhibitor in patients with clinical ASCVD at very high risk whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin and ezetimibe [4]. The National Lipid Association (NLA) issued a similar recommendation in 2020, adding that cost-effectiveness improves substantially at the drug's post-2019 reduced list price [11].

What Praluent Is and Is Not Approved For

Alirocumab is FDA-approved for three indications: primary hyperlipidemia (including HeFH) in adults, reduction of cardiovascular risk in adults with established ASCVD, and HoFH in adults and pediatric patients aged 8 years and older [10].

Praluent is not FDA-approved for weight loss. It is not a GLP-1 receptor agonist. While some patients on PCSK9 inhibitors report modest weight changes, these are not clinically significant, and no BCBS plan covers Praluent for weight management. If a prior authorization request lists weight loss as the indication, it will be denied.

Alirocumab dosing starts at 75 mg subcutaneously every two weeks. If LDL-C response is insufficient after 4 to 8 weeks, the dose may be increased to 150 mg every two weeks or 300 mg every four weeks. The choice between biweekly and monthly dosing can affect BCBS coverage. Some plans only authorize the 75 mg biweekly regimen initially and require a separate authorization for dose escalation [10].

Comparing BCBS Coverage with Other Major Insurers

BCBS coverage for Praluent generally tracks with other large commercial insurers in terms of structure, though specific details differ.

Aetna requires prior authorization with an LDL threshold of 70 mg/dL for ASCVD patients on maximally tolerated statin plus ezetimibe, closely matching the ACC/AHA guideline. UnitedHealthcare uses a similar framework but has historically required a longer statin trial period (12 weeks vs. 8 weeks for some BCBS affiliates). Cigna places Praluent on its specialty tier with a prior authorization requirement and has been among the more restrictive plans in defining statin intolerance.

The BCBS Federal Employee Program, despite being government-funded, tends to be more accessible than Medicare Part D for PCSK9 inhibitor coverage. Medicare Part D plans often impose quantity limits and more stringent step therapy requirements, and patients cannot use manufacturer copay cards [12].

For patients comparing plans during open enrollment, the key variables to evaluate are: formulary tier placement, copay vs. coinsurance structure, step therapy requirements (specifically whether ezetimibe is mandatory before PCSK9 approval), and whether the plan uses a copay accumulator program.

Tips for Getting Praluent Approved on Your BCBS Plan

Start with documentation. Before the prescriber submits the prior authorization, ensure the medical record contains: a fasting lipid panel from the past 30 days, a complete medication history showing all statins and non-statin lipid agents tried (with doses, dates, and reasons for discontinuation), documentation of any adverse effects, and genetic testing or clinical scoring for FH if applicable.

Ask the prescriber to reference the ACC/AHA 2018 guideline and the ODYSSEY OUTCOMES trial data directly in the prior authorization form. Specific trial citations carry more weight than general statements about cardiovascular risk.

If the initial request is denied, file the appeal within the plan's stated deadline (typically 180 days from the denial date, though some affiliates allow only 60 days). Request a peer-to-peer review, which allows the prescribing physician to speak directly with the plan's medical director. Peer-to-peer reviews have a higher overturn rate than written appeals alone.

Patients with documented statin intolerance to two or more agents at any dose should request that the prescriber complete a statin intolerance attestation form, which several BCBS affiliates provide as a standalone document. This form, when properly completed, can bypass the standard step therapy sequence entirely.

Monitor LDL levels at 4 to 8 weeks after starting alirocumab 75 mg every two weeks, and submit the follow-up lipid panel to the plan proactively before the reauthorization deadline.